FDA, drugmakers agree to hike fees 6%; Pfizer extends Icagen offer by 24 hours;

@FiercePharma: Serious infections in AMD patients injected off-label with Avastin. Supports Genentech case that repackaging = risky Report | Follow @FiercePharma

> The FDA and drugmakers have agreed to hike user fees by 6% over the next 5 years as part of the reauthorization of the Prescription Drug User Fee Act. News

> Pfizer ($PFE) has extended its tender offer for Icagen by 24 hours. The move is an attempt to bring in the 100,000-plus Icagen shares it needs to complete its tender offer. Story

> A Merck ($MRK) subsidiary has sued Kentucky Attorney General Jack Conway, alleging its due-process rights were violated in a Vioxx-related consumer protection case he filed in 2009. Item

> Sagent Pharmaceuticals ($SGNT) got the FDA's nod for its version of the muscle relaxant Norflex and plans to launch this quarter. Report

> Dr. Reddy's won FDA approval for its OTC version of Sanofi's ($SNY) Allegra-D 24 Hour allergy medication. Story

> GlaxoSmithKline ($GSK) bought another 600,000 of its own shares in its ongoing buyback program at prices ranging from 1,287.5 pence to 1,316.5 pence per share. Article

> Lupin Pharmaceuticals won FDA approval for its extended-release version of the Tramadol painkiller, a knockoff of Ortho-McNeil-Janssen's Ultram ER. Piece

Biotech News

@FierceBiotech: Analyst: Benlysta's shortcomings offer blockbuster opening for new lupus drugs. News | Follow @FierceBiotech

@JohnCFierce: Give the big media groups a Ph1/2 cancer drug story success and it spreads like wildfire. Diabetes, etc? Not so much. | Follow @JohnCFierce

@RyanMFierce: Just saw this report about a small EDC player called MedNet Solutions, sort of David and Goliath/Oracle story Story | Follow @RyanMFierce

> ReNeuron cleared to proceed with groundbreaking stem cell study. Article

> Cash-strapped Oxigene lays off staffers, shelves PhIII study. More

> Delcath shares slump after chemo system fails to deliver in PhII cohort. News

> Roche CEO Schwan believes diagnostics will be key to success. Report

> Beleaguered Xoma CEO Engle turns in his walking papers. Story

> Jennerex cheered by early efficacy data for cancer-killing virus. Details

Manufacturing News

> Promega adding molecular-biology capacity with new plant. More

> Fareva moves into U.S. with Pfizer plant buy. Story

> Dairy JV nabs India's excipients maker Brahmar. News

> Two CMOs to cut more than 100 jobs in NY, Ireland. Report

> BASF raises excipient, API prices another 10%. Article

> Baxter pumps up lyophilization capacity at Halle plant. Details

Vaccine News

> New strain of H5N1 lacks vax protection. News

> Emory University recieves $26M from NIH. Story

> Infant rotavirus shots may benefit the unvaccinated. Report

> IOM: Vaccines cause very few side effects. Article

> CDC: Teen HPV vaccination rates lagging. Details

And Finally... Scientists found antibiotic-resistant features in the DNA of 30,000-year-old bacteria. Report

Suggested Articles

Merck's Keytruda has new long-term survival results that the drugmaker hopes will help bolster its position in first-line NSCLC.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.